Freenome, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| FRNM | NEO | PSNL | BLLN | ADPT | GRAL | |
|---|---|---|---|---|---|---|
| Market cap | 1.42B | 2.08B | 1.69B | 4.39B | 4.08B | 6.14B |
| P/E (TTM) | — | — | — | 141.0 | — | — |
| Forward P/E | -5.5 | 47.8 | -16.8 | 62.7 | -141.7 | -16.7 |
| Price/book | -0.2 | 2.6 | 7.1 | 8.1 | 28.5 | 2.4 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +24.25% | +72.71% | +92.21% | −14.57% | +64.12% | +98.25% |
| Today | −16.22% | −0.92% | −1.25% | −5.12% | −3.47% | −2.28% |
The closest companies by business and industry (Diagnostics & Research). Prices may be delayed up to 15 min.
Latest news
All FRNM news ›Updated Freenome CRC Blood Test Detects 18.2% of Advanced Precancerous Lesions
Freenome reports 18.2% sensitivity for advanced precancerous lesions and 80.4% for colorectal cancer with its updated blood screening test. For clinicians, the central question is whether improved precancerous lesion detection will…
New version of Freenome's blood test shows improved detection of advanced precancerous colorectal lesions
Freenome announced improved clinical validation results for its updated SimpleScreen™ CRC blood test, showing an 18.2% sensitivity for advanced precancerous lesions (APLs), up from 13.7% in the original test. Sensitivity for high-grade…
Freenome to Present New Validation Data for Next-Generation CRC Screening Test in Late-Breaking Oral Presentation at ACG 2026
Detailed results will be presented at ACG on October 14, 2026. The first-generation test received FDA approval in July 2026 and launched commercially in the United States through Abbott Cancer Diagnostics in late September. FDA approved…
Abbott launches Freenome’s colorectal cancer screening test
Abbott will sell Freenome’s SimpleScreen CRC test in the U.S. alongside the Cologuard Plus stool-based test it gained in the $21 billion acquisition of Exact Sciences. The American Cancer Society recommends blood-based tests as a…
Roche reports 17.4% passive stake in Freenome
Freenome (FRNM) develops blood-based cancer screening tests: FDA-approved SimpleScreen CRC, investigational SimpleScreen Lung, and a multiomics AI platform. - [SCHEDULE 13G] Freenome, Inc. Passive Investment Disclosure (>5%) Roche reports…
Freenome CEO has 71,920 shares withheld for taxes
CEO Elliott Aaron Matthew had 71,920 shares withheld at $15.25 on Sept. 2, 2026 to cover RSU tax obligations, a non-market move leaving him with 345,976 shares. Freenome CEO has 71,920 shares withheld for taxes Freenome’s CEO had shares…
From articles in the 4Search news index.